Back

Plasma amyloid-beta levels and risk of new-onset atrial fibrillation in the general population

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: When is the time to implement novel biomarkers routinely? Biomarkers ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Zuolin Lu

Chinese Academy of Medical Sciences, Beijing (China)

3 More presentations in this session

Presentation thumbnail
State of the art lecture - when is the time to implement novel biomarkers routinely?
Professor B. Ference (Cambridge, GB)
Slides Video
Presentation thumbnail
Association of fatal and non-fatal adverse health outcomes with urinary peptides reflecting collagen I turnover
Doctor J. Melgarejo (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Panel discussion.
Video

Access the full session

Session thumbnail
When is the time to implement novel biomarkers routinely?
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Plasma levels of amyloid beta 1-40 are associated with ultrasonographic morphological characteristics related with carotid plaque vulnerability in individuals without cardiovascular disease
thumbnail
Congress Presentation
Atrial fibrillation is associated with worse outcome in patients with wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
The association between low-grade inflammation, echocardiographic measures of left atrial structure and function, and long-term risk of atrial fibrillation in the general population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources